These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 24407515

  • 1. Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells.
    Sokolosky M, Chappell WH, Stadelman K, Abrams SL, Davis NM, Steelman LS, McCubrey JA.
    Cell Cycle; 2014; 13(5):820-33. PubMed ID: 24407515
    [Abstract] [Full Text] [Related]

  • 2. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
    Ito H, Ichiyanagi O, Naito S, Bilim VN, Tomita Y, Kato T, Nagaoka A, Tsuchiya N.
    BMC Cancer; 2016 Jul 07; 16():393. PubMed ID: 27387559
    [Abstract] [Full Text] [Related]

  • 3. GSK-3β: a key regulator of breast cancer drug resistance.
    Martelli AM, Buontempo F, Evangelisti C.
    Cell Cycle; 2014 Jul 07; 13(5):697-8. PubMed ID: 24526116
    [No Abstract] [Full Text] [Related]

  • 4. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
    Jordan NJ, Dutkowski CM, Barrow D, Mottram HJ, Hutcheson IR, Nicholson RI, Guichard SM, Gee JM.
    Breast Cancer Res; 2014 Jan 23; 16(1):R12. PubMed ID: 24457069
    [Abstract] [Full Text] [Related]

  • 5. Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.
    Steelman LS, Navolanic P, Chappell WH, Abrams SL, Wong EW, Martelli AM, Cocco L, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, McCubrey JA.
    Cell Cycle; 2011 Sep 01; 10(17):3003-15. PubMed ID: 21869603
    [Abstract] [Full Text] [Related]

  • 6. Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells.
    Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Steelman LS, McCubrey JA.
    Oncotarget; 2011 Aug 01; 2(8):610-26. PubMed ID: 21881167
    [Abstract] [Full Text] [Related]

  • 7. GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.
    Abrams SL, Akula SM, Meher AK, Steelman LS, Gizak A, Duda P, Rakus D, Martelli AM, Ratti S, Cocco L, Montalto G, Cervello M, Ruvolo P, Libra M, Falzone L, Candido S, McCubrey JA.
    Cells; 2021 Apr 06; 10(4):. PubMed ID: 33917370
    [Abstract] [Full Text] [Related]

  • 8. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
    Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, Karlin KL, Westbrook TF, Heiser LM, Anur P, Spellman P, Guichard SM, Smith PD, Davies BR, Klinowska T, Lee AV, Mills GB, Rimawi MF, Hilsenbeck SG, Gray JW, Joshi A, Osborne CK, Schiff R.
    Breast Cancer Res; 2014 Sep 11; 16(5):430. PubMed ID: 25212826
    [Abstract] [Full Text] [Related]

  • 9. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy.
    Sokolosky ML, Stadelman KM, Chappell WH, Abrams SL, Martelli AM, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, Steelman LS, McCubrey JA.
    Oncotarget; 2011 Jul 11; 2(7):538-50. PubMed ID: 21730367
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells.
    Kim EY, Kim A, Kim SK, Kim HJ, Chang J, Ahn CM, Chang YS.
    Respir Res; 2014 Feb 26; 15(1):26. PubMed ID: 24571487
    [Abstract] [Full Text] [Related]

  • 11. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.
    Adv Enzyme Regul; 2006 Feb 26; 46():249-79. PubMed ID: 16854453
    [Abstract] [Full Text] [Related]

  • 12. Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression.
    Hall BA, Kim TY, Skor MN, Conzen SD.
    Breast Cancer Res Treat; 2012 Sep 26; 135(2):469-79. PubMed ID: 22842983
    [Abstract] [Full Text] [Related]

  • 13. GSK-3β at the crossroads in the signalling of heart preconditioning: implication of mTOR and Wnt pathways.
    Vigneron F, Dos Santos P, Lemoine S, Bonnet M, Tariosse L, Couffinhal T, Duplaà C, Jaspard-Vinassa B.
    Cardiovasc Res; 2011 Apr 01; 90(1):49-56. PubMed ID: 21233250
    [Abstract] [Full Text] [Related]

  • 14. MicroRNA-3646 Contributes to Docetaxel Resistance in Human Breast Cancer Cells by GSK-3β/β-Catenin Signaling Pathway.
    Zhang X, Zhong S, Xu Y, Yu D, Ma T, Chen L, Zhao Y, Chen X, Yang S, Wu Y, Tang J, Zhao J.
    PLoS One; 2016 Apr 01; 11(4):e0153194. PubMed ID: 27045586
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.
    Chen BW, Chen W, Liang H, Liu H, Liang C, Zhi X, Hu LQ, Yu XZ, Wei T, Ma T, Xue F, Zheng L, Zhao B, Feng XH, Bai XL, Liang TB.
    Mol Cancer Ther; 2015 Aug 01; 14(8):1805-15. PubMed ID: 26026051
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.
    Leung E, Kim JE, Rewcastle GW, Finlay GJ, Baguley BC.
    Cancer Biol Ther; 2011 Jun 01; 11(11):938-46. PubMed ID: 21464613
    [Abstract] [Full Text] [Related]

  • 17. Mechanism of zinc-induced phosphorylation of p70 S6 kinase and glycogen synthase kinase 3beta in SH-SY5Y neuroblastoma cells.
    An WL, Bjorkdahl C, Liu R, Cowburn RF, Winblad B, Pei JJ.
    J Neurochem; 2005 Mar 01; 92(5):1104-15. PubMed ID: 15715661
    [Abstract] [Full Text] [Related]

  • 18. Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment.
    Cao J, Huang W.
    PLoS One; 2016 Mar 01; 11(2):e0149388. PubMed ID: 26872016
    [Abstract] [Full Text] [Related]

  • 19. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.
    Steelman LS, Navolanic PM, Sokolosky ML, Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Wong EW, Stadelman KM, Terrian DM, Leslie NR, Martelli AM, Stivala F, Libra M, Franklin RA, McCubrey JA.
    Oncogene; 2008 Jul 03; 27(29):4086-95. PubMed ID: 18332865
    [Abstract] [Full Text] [Related]

  • 20. Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9.
    Jiang M, Huang O, Zhang X, Xie Z, Shen A, Liu H, Geng M, Shen K.
    Molecules; 2013 Jan 08; 18(1):701-20. PubMed ID: 23299550
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.